Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROAIR HFA vs ACETIC ACID W/ HYDROCORTISONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm
Treatment of superficial bacterial infections of the external auditory canal (otitis externa) and associated inflammation.
Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
Terminal elimination half-life: 3.8 to 5 hours; clinically, this supports a dosing interval of every 4-6 hours as needed for symptom relief.
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
Primarily metabolized by catechol-O-methyltransferase (COMT) and to a lesser extent by sulfation; not metabolized by CYP450 enzymes.
Acetic acid is metabolized via the Krebs cycle to carbon dioxide and water. Hydrocortisone is primarily metabolized in the liver.
Renal: approximately 72% as unchanged drug and metabolites; fecal: approximately 10%; biliary: minimal.
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Approximately 94% bound to human serum albumin.
Hydrocortisone: ~90% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid: negligible binding.
Vd: 1.9 to 2.7 L/kg; this large Vd indicates extensive distribution into tissues, including lung tissue.
Hydrocortisone: Vd ~0.3–0.5 L/kg (systemic); topical application results in negligible systemic distribution.
Inhalation: approximately 10-20% of the administered dose reaches the lungs; the remainder is swallowed and undergoes first-pass metabolism resulting in negligible oral bioavailability.
Topical: ~1–5% of hydrocortisone absorbed through intact skin; higher with inflamed skin or occlusion. Acetic acid: negligible systemic absorption.
No dosage adjustment required for renal impairment.
No dose adjustment required for acetic acid. Hydrocortisone is minimally affected by renal impairment; no specific adjustment recommended.
No dosage adjustment required for hepatic impairment.
No dose adjustment required for acetic acid. For hydrocortisone, use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reducing frequency or dose, though no specific guidelines exist.
Children 4-11 years: Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise. Children <4 years: Safety and efficacy not established.
Safety and efficacy not established in pediatric patients; use not recommended.
No specific dose adjustment; use with caution due to potential for decreased renal function and increased sensitivity to beta-agonists.
No specific dose adjustment required. Use caution due to potential skin atrophy and systemic absorption; limit duration to minimum effective course.
Not applicable; no black box warning.
Not applicable.
Paradoxical bronchospasm may occur,Cardiovascular effects: increased heart rate, blood pressure, or ECG changes,Immediate hypersensitivity reactions,Potentially severe hypokalemia,May exacerbate diabetes and ketoacidosis
For otic use only; not for ophthalmic or systemic use.,Prolonged use may lead to fungal or bacterial superinfection.,Discontinue if irritation or sensitization develops.
Hypersensitivity to albuterol or any component of the formulation
Hypersensitivity to any component.,Viral or fungal infections of the external ear (e.g., herpes simplex, varicella).,Perforated tympanic membrane (risk of ototoxicity).
No significant food interactions. Avoid caffeine and stimulants as they may increase cardiovascular side effects (tachycardia, palpitations). No dietary restrictions required.
No clinically relevant food interactions. No specific dietary restrictions.
FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate caused fetal malformations (cleft palate, limb defects) at doses 0.4-1.2 times the maximum human daily inhalation dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk. For trimester-specific risks: first trimester: potential for orofacial clefts and limb defects; second/third trimesters: risk of maternal tachycardia and hypoglycemia in neonate; labor inhibition near term; possible neonatal transient hypoglycemia.
Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed with topical use. Systemic absorption is minimal with small-area application. Avoid prolonged use on large areas, occlusive dressings, or high-potency steroids. Acetic acid has no known teratogenic risk.
Albuterol is excreted into human breast milk in small amounts (M/P ratio not established). No reported adverse effects in nursing infants. Use with caution in lactating women; benefit of breastfeeding should outweigh potential risk to infant. Monitor infant for signs of beta-adrenergic stimulation (tachycardia, irritability).
Minimal systemic absorption of topical hydrocortisone and acetic acid; unlikely to affect the breastfed infant. Use on limited areas, avoid application to breast or nipple area. M/P ratio not established.
No specific dose adjustment required; however, pharmacokinetic changes in pregnancy (increased volume of distribution, increased clearance) may theoretically require dose frequency adjustment. Use the lowest effective dose and monitor clinical response. No dose adjustment needed based on current evidence.
No dosing adjustments required for pregnancy. Use lowest effective dose for shortest duration to minimize systemic absorption.
Primarily a rescue inhaler for acute asthma exacerbations. Not for maintenance therapy. Shake well before each use. Prime with 3 test sprays when new or not used for >2 weeks. Use spacer device to improve lung deposition and reduce oropharyngeal side effects. Monitor for paradoxical bronchospasm. Tachycardia and hypokalemia can occur with overuse. Replace canister after 200 actuations.
Combination otic suspension for external otitis. Ensure tympanic membrane is intact before use; perforation risks ototoxicity. Shake well before instillation. Use for no longer than 10 days to avoid fungal overgrowth or adrenal suppression. Warm bottle in hands to avoid caloric vertigo. Contraindicated in viral or fungal infections of the ear canal.
Use only as needed for shortness of breath, wheezing, or chest tightness.,Do not use more frequently than prescribed; overuse can lead to serious side effects.,Shake the inhaler vigorously for 5 seconds before each spray.,Prime the inhaler by releasing 3 test sprays into the air before first use or if not used for more than 2 weeks.,Use a spacer device if prescribed to improve medication delivery to the lungs.,Rinse mouth with water after each use to prevent thrush (oral fungal infection).,Seek immediate medical help if symptoms worsen or if you need more than 2 puffs per week for relief.,Store at room temperature away from moisture and heat; do not freeze.
For ear use only. Do not swallow or put in eyes.,Lie on side with affected ear upward for 5 minutes after instillation.,Keep ear clean and dry while using the medication.,Complete full course even if symptoms improve.,Do not use if you have a perforated eardrum; seek medical evaluation first.,Shake the bottle well before each use.
No interactions on record
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROAIR HFA vs ACETIC ACID W/ HYDROCORTISONE, answered by our medical review team.
PROAIR HFA is a Beta-2 Agonist Bronchodilator that works by Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.. ACETIC ACID W/ HYDROCORTISONE is a Corticosteroid that works by Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROAIR HFA and ACETIC ACID W/ HYDROCORTISONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROAIR HFA is: Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.. The standard adult dose of ACETIC ACID W/ HYDROCORTISONE is: 1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROAIR HFA and ACETIC ACID W/ HYDROCORTISONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROAIR HFA is classified as Category C. FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate caused fetal malformations (cleft palate, limb defects) at dos. ACETIC ACID W/ HYDROCORTISONE is classified as Category D/X. Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.